Matching articles for "Merilog"
In Brief: Kirsty — An Insulin Aspart Interchangeable with NovoLog (online only)
The Medical Letter on Drugs and Therapeutics • November 10, 2025; (Issue 1741)
The FDA has approved Kirsty (Biocon), a biosimilar
to rapid-acting insulin aspart (NovoLog), for treatment
of type 1 or type 2 diabetes. Kirsty is the
first rapid-acting insulin to become available in
the...
The FDA has approved Kirsty (Biocon), a biosimilar
to rapid-acting insulin aspart (NovoLog), for treatment
of type 1 or type 2 diabetes. Kirsty is the
first rapid-acting insulin to become available in
the US that has received interchangeability status
with NovoLog; Merilog, another insulin aspart
biosimilar, was approved earlier but has not received
interchangeability status with NovoLog.
In Brief: Merilog — A NovoLog Biosimilar
The Medical Letter on Drugs and Therapeutics • June 23, 2025; (Issue 1731)
The FDA has approved Merilog (Sanofi), a biosimilar to
rapid-acting insulin aspart (NovoLog), for treatment of
patients with type 1 or type 2 diabetes. Merilog is the
first rapid-acting insulin biosimilar...
The FDA has approved Merilog (Sanofi), a biosimilar to
rapid-acting insulin aspart (NovoLog), for treatment of
patients with type 1 or type 2 diabetes. Merilog is the
first rapid-acting insulin biosimilar product to become
available in the US.